Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-08

Study Completion Date

2016-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, single-center, open-label, 3+3 dose escalation Phase 1 safety study. Adults with newly diagnosed GBM or gliosarcoma will receive macitentan in addition to the standard of care treatment for GBM. The study consists of a screening period, a treatment period, and a 30-day safety follow up period. The treatment period includes 6 weeks of concurrent therapy (macitentan+RT+TMZ), 4 weeks of monotherapy (macitentan) and 12 cycles of maintenance therapy (macitentan+TMZ). The study will end when the last treated subject has completed study treatment and the 30-day safety follow-up period.

The planned duration of the study is approximately 34-38 months depending on the number of dose levels and cohorts of subjects enrolled. Subject participation in the study will be for approximately 16 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

NCT01499251

Glioblastoma

TERMINATED PHASE1

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

NCT00200161

Glioblastoma Gliomas

COMPLETED PHASE2

Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme

NCT01822275

Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)

TERMINATED PHASE2

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT00884741

Glioblastoma Gliosarcoma Supratentorial Glioblastoma

COMPLETED PHASE3

Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme

NCT00544817

Glioblastoma Multiforme

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Macitentan in combination with RT & TMZ

Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.

Group Type EXPERIMENTAL

Macitentan in combination with RT and TMZ

Intervention Type DRUG

Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Macitentan in combination with RT and TMZ

Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Temodar (temozolomide [TMZ]) macitentan Radiotherapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects at least 18 years of age
* Histologically proven supratentorial GBM or gliosarcoma
* Use of effective contraception by women of childbearing potental.
* Use of effective contraception by fertile males with a female partner of childbearing potential.
* Interval of at least 3 weeks after biopsy or open surgery and able to begin study treatment.
* Result from a post-operative contrast-enhanced brain MRI within 72 hours after surgery or biopsy.
* Adequate bone marrow function
* Karnofsky Performance Score of at least 70.

Exclusion Criteria

* Prior treatment for glioblastoma or gliosarcoma.
* Evidence of leptomeningeal spread of glibolastoma or gliosarcoma.
* Tumor foci below the tentorium or beyond the cranial vault.
* Evidence of recent hemorrhage on post-operative contrast enhanced brain MRI (except hemosiderin, resolving hemorrhage changes related to surgery, presence of punctuate hemorrhage in tumor).
* Aspartate aminotransferase or alanine aminotransferase \> 3 times the upper limit of normal.
* Supine systolic blood pressure \< 100 mmHg or diastolic blood pressure \< 50 mmHg.
* Medical history of orthostatic hypotension.
* International normalized ratio \> 1.5 on anticoagulant therapy, active bleeding on low molecular weight heparin, or chronic condition with a high risk of bleeding.
* Severe renal impairment.
* Severe hepatic impairment.
* Severe, active co-morbidity: (e.g. cardiac disease; respiratory disease; chronic hepatitis; hemtological and bone marrow diseases; severe malabsoprtion; human immunodeficiency virus).
* No concurrent strong CYP3A4 inducers or inhibitors.
* No investigational drug within 4 weeks of starting study treatment.
* Any life-threatening condition that could affect protocol compliance.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No